title: The macrophage: Switches from a passenger to a driver during anticancer therapy.
abstract: We have recently discovered that BRAF inhibitors induce potent macrophage responses that confer melanoma resistance to therapy. Our studies lay a foundation for the hypothesis that macrophages switch their role from a passenger to a driver for tumor survival during therapeutic treatment, suggesting that agents that target macrophages can be an important component of "cocktail" anticancer therapy.
authors.affiliation: Center for Drug Evaluation and Research; US Food and Drug Administration ; Silver Spring, MD USA.
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.affiliation: Center for Drug Evaluation and Research; US Food and Drug Administration ; Silver Spring, MD USA.
authors.forename: Gerald M
authors.initials: GM
authors.lastname: Feldman
authors.affiliation: The Wistar Institute ; Philadelphia, PA USA.
authors.forename: Meenhard
authors.initials: M
authors.lastname: Herlyn
authors.affiliation: The Wistar Institute ; Philadelphia, PA USA.
authors.forename: Russel E
authors.initials: RE
authors.lastname: Kaufman
keywords: BRAF inhibitor; macrophage; melanoma; targeted therapy